EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies
- PMID: 31672775
- DOI: 10.1136/annrheumdis-2019-216114
EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies
Abstract
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. In view of this scenario, the European League Against Rheumatism (EULAR) promoted and supported an international collaborative study (EULAR SS Task Force) aimed at developing the first EULAR evidence and consensus-based recommendations for the management of patients with SjS with topical and systemic medications. The aim was to develop a rational therapeutic approach to SjS patients useful for healthcare professionals, physicians undergoing specialist training, medical students, the pharmaceutical industry and drug regulatory organisations following the 2014 EULAR standardised operating procedures. The Task Force (TF) included specialists in rheumatology, internal medicine, oral health, ophthalmology, gynaecology, dermatology and epidemiology, statisticians, general practitioners, nurses and patient representatives from 30 countries of the 5 continents. Evidence was collected from studies including primary SjS patients fulfilling the 2002/2016 criteria; when no evidence was available, evidence from studies including associated SjS or patients fulfilling previous sets of criteria was considered and extrapolated. The TF endorsed the presentation of general principles for the management of patients with SjS as three overarching, general consensus-based recommendations and 12 specific recommendations that form a logical sequence, starting with the management of the central triplet of symptoms (dryness, fatigue and pain) followed by the management of systemic disease. The recommendations address the use of topical oral (saliva substitutes) and ocular (artificial tear drops, topical non-steroidal anti-inflammatory drugs, topical corticosteroids, topical CyA, serum tear drops) therapies, oral muscarinic agonists (pilocarpine, cevimeline), hydroxychloroquine, oral glucocorticoids, synthetic immunosuppressive agents (cyclophosphamide, azathioprine, methotrexate, leflunomide and mycophenolate), and biological therapies (rituximab, abatacept and belimumab). For each recommendation, levels of evidence (mostly modest) and TF agreement (mostly very high) are provided. The 2019 EULAR recommendations are based on the evidence collected in the last 16 years in the management of primary 2002 SjS patients and on discussions between a large and broadly international TF. The recommendations synthesise current thinking on SjS treatment in a set of overarching principles and recommendations. We hope that the current recommendations will be broadly applied in clinical practice and/or serve as a template for national societies to develop local recommendations.
Keywords: autoimmune diseases; sjøgren's syndrome; treatment.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: MR-C reported consultancy for BMS, Gilead; FB reported consultancy GSK, UCB, ONO, Roche; MB consultancy and/or unrestricted grants from Medimmune, Amgen, GSK, Janssen, AbbVie; SB Participation in Abbvie Advisory Board; RP for Abbvie, Novartis, Ab2 Bio ltd, Celltrion healthcare; RC: speaker’s and/or consultation fee from: Abbvie, BMS, Celgene, Gilead, Janssen Cilag, Lilly, MSD, Novartis, Pfizer, Roche and Sanofi; MR reported consultancy for Abbvie, BMS, Celgene, Janssen Cilag, Novartis, Pfizer, Roche and Sanofi; W-FN reported consultancy for GSK, Novartis, BMS, MedImmune and Abbvie; AGT reported Research Grants From Pfizer, Novartis, Abbvie, Genesis, GSK, Janssen, Eli-Lilly, Through The Research Accounts Of The University Of Athens; CHS: Consultant for Novartis in 2018; PW consultant for Roche, Novartis, Pfizer, Abbvie, Lilly, Gedeon-Richter, Sandoz, Medac, MSD, Sanofi-Aventis. TM reported consultancy Novartis; BAF reported consultancy for Novartis, Roche, MedImmune, BMS.
Comment in
-
First EULAR recommendations for Sjögren syndrome published.Nat Rev Rheumatol. 2020 Jan;16(1):2. doi: 10.1038/s41584-019-0349-9. Nat Rev Rheumatol. 2020. PMID: 31780793 No abstract available.
Similar articles
-
Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome.RMD Open. 2019 Oct 28;5(2):e001064. doi: 10.1136/rmdopen-2019-001064. eCollection 2019. RMD Open. 2019. PMID: 31749986 Free PMC article.
-
Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome.Drugs Aging. 2021 Apr;38(4):265-284. doi: 10.1007/s40266-021-00838-6. Epub 2021 Feb 23. Drugs Aging. 2021. PMID: 33619703 Review.
-
Sjogren's syndrome from the perspective of ophthalmology.Clin Immunol. 2017 Sep;182:55-61. doi: 10.1016/j.clim.2017.04.017. Epub 2017 May 2. Clin Immunol. 2017. PMID: 28476437 Review.
-
Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.Expert Opin Pharmacother. 2013 Feb;14(3):279-89. doi: 10.1517/14656566.2013.767333. Epub 2013 Jan 25. Expert Opin Pharmacother. 2013. PMID: 23346917 Review.
-
Management of patients presenting with Sjogren's syndrome.Best Pract Res Clin Rheumatol. 2006 Aug;20(4):791-807. doi: 10.1016/j.berh.2006.05.003. Best Pract Res Clin Rheumatol. 2006. PMID: 16979538 Review.
Cited by
-
The Role of Decorin in Autoimmune and Inflammatory Diseases.J Immunol Res. 2022 Aug 17;2022:1283383. doi: 10.1155/2022/1283383. eCollection 2022. J Immunol Res. 2022. PMID: 36033387 Free PMC article. Review.
-
Sjögren's syndrome: a systemic autoimmune disease.Clin Exp Med. 2022 Feb;22(1):9-25. doi: 10.1007/s10238-021-00728-6. Epub 2021 Jun 7. Clin Exp Med. 2022. PMID: 34100160 Free PMC article. Review.
-
Mycophenolate for the Treatment of Primary Sjögren's Syndrome.J Transl Int Med. 2020 Sep 25;8(3):146-149. doi: 10.2478/jtim-2020-0023. eCollection 2020 Sep. J Transl Int Med. 2020. PMID: 33062590 Free PMC article. Review.
-
Interstitial Lung Disease in Primary Sjögren's Syndrome: Risk factors for occurrence and radiographic progression.Sarcoidosis Vasc Diffuse Lung Dis. 2024 Sep 24;41(3):e2024035. doi: 10.36141/svdld.v41i3.15548. Sarcoidosis Vasc Diffuse Lung Dis. 2024. PMID: 39315979 Free PMC article.
-
Network pharmacology-based strategy to investigate the mechanisms of artemisinin in treating primary Sjögren's syndrome.BMC Immunol. 2024 Feb 12;25(1):16. doi: 10.1186/s12865-024-00605-3. BMC Immunol. 2024. PMID: 38347480 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous